IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call showed mixed signals. While there was revenue growth and improved net loss, gross margins declined due to increased costs, and Middle East revenue was excluded from guidance due to conflict. The Q&A revealed stable ASPs and increased market share in the retina segment, but macroeconomic and operational risks persist. The neutral sentiment reflects these balanced positives and negatives, suggesting limited stock price movement.
Key Financial Performance
Full Year Revenue $52.7 million, representing 8% growth year-over-year versus 2024. Growth was driven by increases across every major product category and both U.S. and international businesses.
Fourth Quarter Revenue $14.7 million, representing a 16% year-over-year increase compared to $12.7 million in Q4 2024. Growth was driven primarily by higher retina sales, including PASCAL sales and glaucoma probe sales.
Retina Product Revenue (Q4 2025) $8.9 million, a 22% increase compared to Q4 2024. Growth was driven by higher PASCAL system sales and medical and surgical retina system sales.
Cyclo G6 Glaucoma Product Revenue (Q4 2025) $3.8 million, representing 15% growth year-over-year, driven primarily by higher probe sales.
Gross Profit (Q4 2025) $5.5 million, or a gross margin of 37%, a decrease from $5.6 million (44% gross margin) in Q4 2024. The decline was due to increased manufacturing costs, including tariff developments and lower capitalization of manufacturing overhead as inventory levels declined.
Operating Expenses (Q4 2025) $5.5 million, a decrease of $0.6 million or 10% compared to $6.1 million in Q4 2024, due to expense reduction measures taken in late 2024.
Net Loss (Q4 2025) $0.2 million, or $0.01 per share, compared to a net loss of $0.8 million or $0.05 per share in Q4 2024. Improvement was driven by expense reduction measures.
Non-GAAP Adjusted EBITDA (Q4 2025) $817,000, an improvement of $0.2 million compared to $611,000 in Q4 2024, driven by expense reduction measures.
Cash and Cash Equivalents (End of Q4 2025) $6.0 million, an increase of $0.4 million compared to $5.6 million at the end of Q3 2025. Cash use for 2025 was $2.1 million, a 71% improvement compared to 2024.
Cyclo G6 Probes Sold (Full Year 2025) 57,800 probes, compared to 55,400 in 2024, reflecting increased utilization.
Cyclo G6 Systems Sold (Full Year 2025) 133 systems, compared to 125 in 2024, reflecting increased adoption.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cyclo G6 systems and probes: Sales of Cyclo G6 systems and probes increased, with 15,900 probes sold in Q4 2025 compared to 13,300 in Q4 2024. Full-year sales reached 57,800 probes and 133 systems, showing growth from 2024.
PASCAL retina systems: PASCAL systems saw strong adoption, particularly in the U.S., driven by upgrades and new ophthalmologists choosing the system. Retina product revenue increased by 22% in Q4 2025.
International glaucoma and retina markets: Growth in Europe, Middle East, and Africa for glaucoma probes, despite challenges in the Middle East due to conflict. Retina sales in Asia and Latin America showed steady demand despite macroeconomic challenges.
ENT business expansion in the U.K.: Notable increases in ENT probes and IQ 532 XP systems in the U.K. market.
Cost reduction initiatives: Relocation of G&A functions out of California expected to save $165,000 quarterly starting Q1 2026. Headquarters relocation in 2026 to save $600,000 annually.
Manufacturing transition: Transition to third-party contract manufacturing to reduce costs, with full implementation expected by 2027.
Targeting high-volume MIGS surgeons: Using MedScout software to identify and engage high-volume surgeons for Cyclo G6 adoption.
Regulatory approvals for retina platforms: Pursuing international regulatory approvals to expand the market for retina products.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Conflict in Iran: The ongoing conflict in Iran is materially impacting sales in the Middle East, leading to a significant disruption in revenue from this region.
Macroeconomic conditions in Asia: Shifting macroeconomic conditions, including tariff uncertainties with China and currency pressures in Japan, are negatively affecting commercial activities and sales forecasting in the region.
Manufacturing transition risks: The transition to third-party contract manufacturers, expected to be completed by 2027, poses risks related to operational disruptions and potential delays, which could impact cost reductions and gross margin improvements.
Tariff developments: Increased product costs associated with tariff developments throughout the year have contributed to higher manufacturing costs and a decline in gross margins.
Inventory and manufacturing overhead: Lower capitalization of manufacturing overhead due to declining inventory levels has negatively impacted gross margins.
Middle East sales exclusion in 2026 guidance: The exclusion of Middle East revenue from 2026 guidance due to ongoing conflicts represents a potential limitation on revenue growth.
Seasonality of revenue: Seasonal fluctuations in revenue, with the first quarter typically being the weakest, could impact cash flow and financial stability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Revenue is expected to range from $51 million to $53 million, representing a growth of 1% to 5% compared to 2025, excluding Middle East revenue.
Cost Reduction Initiatives: Relocation of certain general and administrative functions out of California is expected to generate approximately $165,000 in quarterly savings starting Q1 2026. Headquarters relocation later in 2026 will further reduce fixed costs by approximately $600,000 annually.
Manufacturing Transition: Transitioning production to lower-cost third-party manufacturers starting in 2026, with full implementation expected by 2027. This is anticipated to significantly reduce cost of goods and improve gross margins over the coming years.
Glaucoma Business Growth: Focus on leveraging the installed base of Cyclo G6 systems and driving higher procedural utilization. Targeting high-volume MIGS surgeons and midrange utilization accounts using MedScout software. Pricing tailwinds and physician relocations are expected to contribute positively to revenue growth in 2026.
Retina Business Expansion: Pursuing international regulatory approvals to unlock new geographies and accelerating the PASCAL installed base replacement cycle domestically. Continued focus on capitalizing on the ongoing upgrade cycle and driving PASCAL adoption.
Cash Flow Expectations: Positive cash flow is expected for the fiscal year 2026, with sequential improvement in quarterly cash generation as inventory is sold and receivables are collected.
Seasonality of Revenue: First quarter is expected to represent 22% of annual revenue, with the fourth quarter being the strongest. Second and fourth quarters are seasonally stronger than the first, while the third quarter typically sees a sequential decline.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How large is the Middle East in terms of revenues for 2026 guidance?
A:The Middle East accounts for 5% of the total revenue base and 10% of the OUS revenue.
Q:Why was the 'other revenue' line sequentially down from Q3 to Q4?
A:The 'other revenue' line is dependent on service product lines and remains relatively flat, fluctuating within $100,000.
Q:Was there a decline in pricing for G6 systems and probe utilization compared to past quarters?
A:No, the decline in consolidated numbers was driven by OUS. In the U.S., ASPs for probes and systems have increased, and volume has picked up.
Q:What is the organic growth rate for the retina segment, and is the company gaining market share?
A:The retina segment has seen small growth due to the acquisition of PASCAL systems, which has become a flagship product. The company is gaining market share, especially with the momentum of PASCAL and MDR approvals globally.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were direct and detailed.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Canada
ENT
East Africa
IQ XP
Middle East
PASCAL system
adoption
base
capitalization manufacturing
compensation
conflict Iran
decline increase
development capitalization
driver
effort
end cash
increase manufacturing
inventory level
lead
manufacturing inventory
manufacturing product
milestone
order
platform
procedure
product tariff
quality
region
relocation
retina
revenue
sale Middle
sale product
tariff development
transition
IRIX Transcript
IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript
Unknown3-26
The earnings call showed mixed signals. While there was revenue growth and improved net loss, gross margins declined due to increased costs, and Middle East revenue was excluded from guidance due to conflict. The Q&A revealed stable ASPs and increased market share in the retina segment, but macroeconomic and operational risks persist. The neutral sentiment reflects these balanced positives and negatives, suggesting limited stock price movement.
IRIDEX Corporation (IRIX) Q3 2025 Earnings Call Prepared Remarks Transcript
Unknown11-11
The earnings call shows mixed signals: positive revenue growth and strategic initiatives, but concerns about supply chain disruptions and competitive pressures. While there is a clear path to profitability, the current financials show a net loss and reduced gross margins. The absence of clear shareholder return plans and the absence of positive analyst sentiment in the Q&A further support a neutral outlook. Without market cap data, the stock's sensitivity to these factors is uncertain, suggesting a neutral prediction for the stock price over the next two weeks.
IRIDEX Corporation (NASDAQ:IRIX) Q1 2025 Earnings Call Transcript
Positive5-15
The earnings call summary indicates positive trends, such as achieving adjusted EBITDA positivity, cost reductions, and revenue growth. The strategic partnership with Novel Inspiration and focus on expense management are promising. While risks and uncertainties exist, including regulatory and partnership risks, the Q&A reveals minimal impact from tariffs and plans for cash flow positivity. Despite unchanged EPS, the overall sentiment is positive due to operational improvements and strategic initiatives, suggesting a likely stock price increase of 2% to 8%.
IRIDEX Corporation, Inc. (IRIX) Q1 2025 Earnings Call Transcript
Positive5-13
The earnings call shows strong financial improvement with positive adjusted EBITDA and reduced operating expenses. Despite a net loss, the company is on track for cash flow breakeven in 2025. The strategic investment and increased gross margin are positive signs. However, management's refusal to provide specific revenue targets and ongoing risks like supply chain challenges temper enthusiasm. Overall, the sentiment is positive, with expected growth driven by new product launches and market demand.
IRIX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
